Andreas W Berger, Daniel Schwerdel, Anke Reinacher-Schick, Waldemar Uhl, Hana Algül, Helmut Friess, Klaus-Peter Janssen, Alexander König, Michael Ghadimi, Eike Gallmeier, Detlef K Bartsch, Michael Geissler, Ludger Staib, Andrea Tannapfel, Alexander Kleger, Alica Beutel, Lucas-Alexander Schulte, Marko Kornmann, Thomas J Ettrich, Thomas Seufferlein
The most frequent malignancy of the pancreas is the pancreatic ductal adenocarcinoma (PDAC). Despite many efforts PDAC has still a dismal prognosis. Biomarkers for early disease stage diagnosis as a prerequisite for a potentially curative treatment are still missing. Novel blood-based markers may help to overcome this limitation. Methods: Prior to surgery plasma levels of thrombospondin-2 (THBS2), which was recently published as a novel biomarker, and CA19-9 from 52 patients with histologically proven PDAC were determined, circulating cell-free (cfDNA) was quantified...
2019: Theranostics